Table 1 Patient demographics at the time of bDMARD discontinuation
Type of biologic | All | TNFi(mAb) | TNFi(R/P) | CTLA4-Ig | IL-6Ri | p value |
|---|---|---|---|---|---|---|
| Â | (N = 181) | (N = 95) | (N = 32) | (N = 17) | (N = 37) | |
Age (years) | 49.0 ± 16.7 | 50.8 ± 15.7 | 45.9 ± 17.5 | 49.4 ± 18.2 | 46.8 ± 18.3 | 0.42 |
Female sex, n (%) | 144 (79.6) | 77 (81.1) | 27 (84.4) | 12 (70.6) | 28 (75.7) | 0.62 |
Disease duration (years) | 7.6 ± 9.2 | 5.3 ± 6.9 | 11.2 ± 11.5 | 8.0 ± 7.8 | 10.2 ± 11.3 | < 0.01 |
Current smoking, n (%) | 11 (11.1) | 9 (17.3) | 0 (0) | 1 (9.1) | 1 (4.2) | 0.19 |
bDMARD-naïve, n (%) | 118 (65.2) | 76 (80.1) | 18 (56.3) | 11 (64.7) | 18 (48.6) | < 0.01 |
Discontinuation due to remission, n (%) | 34 (18.8) | 25 (26.3) | 4 (12.5) | 3 (17.6) | 2 (5.4) | 0.03 |
Remission maintenance period (days) | 130.6 ± 185.0 | 162.0 ± 211.0 | 125.3 ± 155.8 | 98.3 ± 140.2 | 69.5 ± 135.7 | 0.06 |
DAS28-CRP | 1.6 ± 0.4 | 1.5 ± 0.39 | 1.7 ± 0.4 | 1.7 ± 0.4 | 1.7 ± 0.4 | < 0.01 |
Boolean remission achieved, n (%) | 61 (33.7) | 34 (35.8) | 18 (56.3) | 1 (5.9) | 8 (21.6) | < 0.01 |
MTX use, n (%) | 142 (78.5) | 70 (73.7) | 29 (90.6) | 10 (58.8) | 33 (89.2) | 0.01 |
MTX dose (mg/week) | 7.1 ± 2.9 | 8.3 ± 3.0 | 7.5 ± 2.4 | 9.0 ± 3.6 | 7.5 ± 2.6 | 0.11 |
Glucocorticoid use, n (%) | 77 (42.5) | 40 (42.1) | 8 (25.0) | 12 (70.6) | 17 (45.9) | 0.02 |
Glucocorticoid dose (mg/day) | 5.9 ± 9.5 | 7.4 ± 12.9 | 4.5 ± 3.6 | 4.9 ± 2.0 | 3.9 ± 2.2 | 0.44 |
ACPA positive, n (%) | 125 (86.2) | 68 (89.5) | 26 (34.2) | 8 (53.3) | 26 (86.7) | 0.54 |
RF positive, n (%) | 114 (77.0) | 57 (75.0) | 15 (62.5) | 13 (86.7) | 29 (87.9) | 0.04 |